Catalent has made a series of strategic investments totaling $652 million-plus to enhance the company capabilities in oral prescription and biologic products. Sherief Shaaban, Vice President, Strategic Ventures & Global Partners, Catalent, provided an update at the DCAT Member Company Announcement Forum on March 20, 2023, at DCAT Week.